KEW Group Launches CancerPlex® Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
Cambridge, Mass., Oct. 25, 2013 – KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the launch of CancerPlex®, a highly versatile and comprehensive gene testing panel to evaluate genetic changes in a patient’s tumor to help oncologists effectively manage treatment options. CancerPlex was developed and validated in KEW’s CLIA laboratory and can be used for examination of the genetic profile of many common cancers.
KEW Group is also developing state-of-the-art evidence-based therapeutic pathways that provide information about when it is appropriate to conduct diagnostic testing, including molecular diagnostics, and how that information can be used in clinical decision support.
“With the addition of KEW CancerPlex, we are providing an important new service to community oncologists by incorporating state-of-the art genomic testing with evidence-based diagnostic and treatment pathways to benefit cancer patients”, said Kathy Behrens Wilsey, CEO of KEW Group Inc. “These services are expected to provide the basis for both current and next generation cancer treatments.”
KEW’s CancerPlex assay utilizes next-generation sequencing to analyze more than 400 known cancer genes involved in cancer initiation and progression. The resulting information from this tumor mutation analysis can be used by physicians to supplement other patient-specific information and assist in the determination of treatment options.